<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088023</url>
  </required_header>
  <id_info>
    <org_study_id>02-000</org_study_id>
    <secondary_id>DFCI Legacy- 03-183</secondary_id>
    <secondary_id>CTEP Grant No.- UO1-CA62490-09</secondary_id>
    <secondary_id>NSC No.- 712783</secondary_id>
    <nct_id>NCT00088023</nct_id>
  </id_info>
  <brief_title>Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness</brief_title>
  <official_title>A Phase I Study of PT-523 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of a short intravenous infusion of&#xD;
      PT-523 to patients with solid tumors who have failed curative or survival prolonging therapy&#xD;
      or for whom no such therapies exist.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are 1) to evaluate the safety of a short intravenous&#xD;
      infusion of PT-523 when administered on days 1, 8, and 15 of a 28-day cycle to patients with&#xD;
      solid tumors who have failed curative or survival prolonging therapy or for whom no such&#xD;
      therapies exist; and 2) to establish the maximum tolerated dose (MTD) and identify the dose&#xD;
      limiting toxicities (DLT) of PT-523.&#xD;
&#xD;
      The secondary objectives of this study are to determine the pharmacokinetics and to evaluate&#xD;
      preliminary efficacy of PT-523.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>December 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT-523 for Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of metastatic or inoperable malignancy, other than leukemia or a primary&#xD;
             central nervous system (CNS) tumor, for which there is no known curative or survival&#xD;
             prolonging palliative therapy, or failure of these therapies .&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Life expectancy greater than or equal to 2 months.&#xD;
&#xD;
          -  ECOG performance status 0 - 2.&#xD;
&#xD;
          -  Adequate organ function and bone marrow reserve.&#xD;
&#xD;
          -  Use of appropriate contraceptive method.&#xD;
&#xD;
          -  Sign patient informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active brain metastases.&#xD;
&#xD;
          -  Presence of third-space fluid collections (pleural effusion, ascites).&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to dosing.&#xD;
&#xD;
          -  Prior chemotherapy or radiation therapy within 3 weeks prior to dosing (6 weeks for&#xD;
             nitrosoureas or mitomycin-C). Prior antifolate therapy is permitted, as long as it has&#xD;
             not been administered within 3 weeks prior to dosing with PT-523.&#xD;
&#xD;
          -  Prior bone marrow transplantation.&#xD;
&#xD;
          -  Presence of uncontrolled serious medical or psychiatric illness.&#xD;
&#xD;
          -  Patients requiring radiation therapy.&#xD;
&#xD;
        There are no limitations on the extent or type of prior therapy received by the patient&#xD;
        other than the time intervals indicated above, as long as the patient has demonstrated&#xD;
        complete recovery from any adverse effects, and fulfills all relevant inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Paul Eder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 19, 2004</study_first_submitted>
  <study_first_submitted_qc>July 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2004</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <keyword>Solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

